Legal Information

Intellectual Property Rights

The contents of this Web site are copyrighted. AstraZeneca Pharmaceuticals LP and AstraZeneca LP, members of the AstraZeneca group of companies (collectively, the "Company"), hereby authorize you to copy documents published on this Web site for non-commercial personal use only, provided that any copy of these documents which you make shall retain all copyright and other proprietary notices and any disclaimer contained on the documents. Except as expressly provided above, you may not otherwise copy, display, download, distribute, modify, reproduce, republish or retransmit any information, text or documents contained in this Web site or any portion thereof in any electronic medium or in hard copy, or create any derivative work based on such images, text or documents, without the express written consent of the Company.

No information or statement contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of the Company, or its affiliates, or any third party. Except as expressly provided above, no information or statement contained herein shall be construed as conferring any license or right under any AstraZeneca group patent, copyright or trademark.

All product names referred to herein are trademarks of the AstraZeneca group of companies, its licensors or joint venture partners unless otherwise indicated.

Disclaimers

The Company has undertaken reasonable efforts to include accurate and up-to-date information on its Web site. However, THIS WEB SITE IS PROVIDED "AS IS" AND THE COMPANY MAKES NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. THE COMPANY DOES NOT WARRANT THAT THE FUNCTIONS CONTAINED IN THE WEB SITE WILL BE UNINTERRUPTED OR ERROR FREE OR THAT THE WEB SITE OR THE SERVER THAT MAKES IT AVAILABLE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED WARRANTIES, SO THE ABOVE EXCLUSION MAY NOT APPLY TO YOU. All users agree that all access and use of this Web site and its content is at their own risk.

Neither the Company nor any other party involved in creating, producing or delivering this Web site shall be liable in any manner for any direct, incidental, consequential, indirect or punitive damages arising out of your access, use or inability to use this Web site, or any errors or omissions in the content.

This Web site may provide links or references to other Internet sites maintained by third parties over whom the Company has no control. Such links are provided merely as a convenience to users of this Web site. The Company takes no responsibility for the content of such sites and makes no representations as to the accuracy or completeness of any information contained in such sites, and shall have no liability for any damages or injuries of any kind arising from such content or information.

Prescribing Information

Product information provided on this site is intended for use by U.S. residents only. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This information is available to the public for educational purposes only; it should not be used for diagnosing or treating a health problem or disease. It is not intended to substitute for consultation with a licensed healthcare provider. The Company cannot answer unsolicited emails requesting personal medical advice; please consult your healthcare provider.

Privacy Statement

Submissions

The Company welcomes inquiries and comments from visitors to this site. However, any communications or information sent by a visitor to a Company-sponsored Web site or to the Company by electronic mail, including questions, comments, data, ideas or know-how, shall be deemed to be non-confidential and shall become the property of the Company, without compensation to the provider of such submissions. The Company shall have no obligation of any kind with respect to such information and may reproduce, publish, disclose, and distribute to others all or any part of such information, without limitation, for any purpose whatsoever. The Company shall be free to use any ideas, concepts, know-how, techniques or inventions contained therein for any purpose, including but not limited to developing, manufacturing and marketing products and services.

Indications and Important Safety Information, including boxed WARNING

  • SYMBICORT is indicated for the long-term maintenance treatment of asthma in patients 12 years and older
  • SYMBICORT is NOT indicated for the relief of acute bronchospasm and should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma
  • SYMBICORT is not indicated in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled short-acting beta2-agonists
  • WARNING: Long-acting beta2-adrenergic agonists may increase the risk of asthma-related death. SYMBICORT should only be used for patients with asthma not adequately controlled on other asthma-controller medications (eg, low- to medium- dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT (see WARNINGS in full Prescribing Information)
  • SYMBICORT does NOT replace fast-acting inhalers and should not be used to treat acute symptoms of asthma
  • SYMBICORT should not be used for transferring patients from systemic corticosteroid therapy. Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids
  • Patients who are receiving SYMBICORT should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason
  • SYMBICORT should be used with caution in patients with cardiovascular disorders. Some patients may experience and increase in blood pressure or heart rate
  • SYMBICORT, like all medications containing sympathomimetic amines, should be used in caution with patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), untreated hypokalemia, thyrotoxicosis, convulsive disorders, and in patients who are unusually responsive to sympathomimetic amines
  • Long-term use of orally inhaled corticosteroids, such as budesonide, a component of SYMBICORT, may affect normal bone metabolism resulting in a loss of bone mineral density. In patients with major risk factors for decreased bone mineral content, such as tobacco use, advanced age, sedentary lifestyle, poor nutrition, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants and corticosteroids), orally inhaled corticosteroids may pose additional risk
  • Rare instances of glaucoma, increase intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteroids, including budesonide, a component of SYMBICORT
  • Lower respiratory tract infections, including pneumonia, have been reported following the inhaled administration of corticosteroids, including budesonide, a component of SYMBICORT. In US clinical studies, the incidence of lower respiratory tract infections, including pneumonia, was low, with no consistent evidence of increased risk for SYMBICORT, compared to placebo
  • SYMBICORT should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks or discontinuation of such agents
  • The most common adverse events ≥5% reported in clinical trials, regardless of relationship to treatment, included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, and stomach discomfort

Please see WARNING in full Prescribing Information

This product information is intended for US Health Care Professionals only.

SYMBICORT is a registered trademark of the AstraZeneca group of companies.

©2007AstraZeneca LP. All rights reserved. 251677 6/07

AstraZeneca